WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406237
CAS#: 345987-15-7
Description: AS601245 is a potent and selective JNK inhibitor. AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. AS601245 and clofibrate have a synergistic effect in inducing cell responses and in affecting the cene expression profile in CaCo-2 colon cancer cells. AS601245 reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. AS601245 shows promising neuroprotective properties.
MedKoo Cat#: 406237
Name: AS601245
CAS#: 345987-15-7
Chemical Formula: C20H16N6S
Exact Mass: 372.11572
Molecular Weight: 372.45
Elemental Analysis: C, 64.50; H, 4.33; N, 22.56; S, 8.61
AS601245 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: AS601245; AS-601245; AS 601245.
IUPAC/Chemical Name: (Z)-2-(benzo[d]thiazol-2(3H)-ylidene)-2-(2-((2-(pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)acetonitrile
InChi Key: AVLYNJZZQYEFEA-XDJHFCHBSA-N
InChi Code: InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,25H,7,10H2,(H,23,24,26)/b19-15+
SMILES Code: N#C/C(C1=NC(NCCC2=CC=CN=C2)=NC=C1)=C3SC4=CC=CC=C4N\3
The following data is based on the product molecular weight 372.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Cerbone A, Toaldo C, Minelli R, Ciamporcero E, Pizzimenti S, Pettazzoni P, Roma G, Dianzani MU, Ullio C, Ferretti C, Dianzani C, Barrera G. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One. 2012;7(6):e40149. doi: 10.1371/journal.pone.0040149. Epub 2012 Jun 28. PubMed PMID: 22761953; PubMed Central PMCID: PMC3386191.
2: Cerbone A, Toaldo C, Pizzimenti S, Pettazzoni P, Dianzani C, Minelli R, Ciamporcero E, Roma G, Dianzani MU, Canaparo R, Ferretti C, Barrera G. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells. PPAR Res. 2012;2012:269751. doi: 10.1155/2012/269751. Epub 2012 Feb 29. PubMed PMID: 22619672; PubMed Central PMCID: PMC3349252.
3: Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2008 Jan;153(1):157-63. Epub 2007 Nov 19. PubMed PMID: 18026128; PubMed Central PMCID: PMC2199388.
4: Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004 Jul;310(1):25-32. Epub 2004 Feb 26. PubMed PMID: 14988419.
